UK
Therapeutic Areas
Septerna Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SEP-479 (PTH1R) | Hypoparathyroidism | Phase 2 |
| SEP-631 (MRGPRX2) | Chronic Spontaneous Urticaria; Other mast cell diseases | Phase 2 |
| TSHR Program | Graves' Disease; Thyroid Eye Disease | IND-Enabling |
| Metabolic Programs (GCGR + Undisclosed, GIPR, GLP-1R) | Obesity and Other Cardiometabolic Diseases | Partnered / Discovery |
Leadership Team at Septerna
JF
Jeffrey Finer
Chief Executive Officer and Co-Founder
GL
Gil Labrucherie
Chief Financial Officer
LB
Liz Bhatt
President and Chief Operating Officer
MA
Mark A. Wilson
Chief Legal Officer
SS
Samira Shaikhly
Chief People Officer
JK
Jae Kim
Chief Medical Officer
DL
Daniel Long
Senior Vice President, Drug Discovery
RL
Robert Lefkowitz
Scientific Founder
AC
Arthur Christopoulos
Scientific Founder
PS
Patrick Sexton
Scientific Founder